Analyst Ratings For Fibrocell Science Inc (NASDAQ:FCSC)
Today, HC Wainwright reiterated its Buy rating on Fibrocell Science Inc (NASDAQ:FCSC) with a price target of $22.00.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Fibrocell Science Inc (NASDAQ:FCSC) is Buy with a consensus target price of $16.00 per share, a potential 764.86% upside.
Some recent analyst ratings include
- 3/28/2019-Fibrocell Science Inc (NASDAQ:FCSC) had its Buy rating reiterated by HC Wainwright with a $22.00 price target
- 4/2/2018-Fibrocell Science Inc (NASDAQ:FCSC) had its Buy rating reiterated by Griffin Securities
- On 8/22/2018 John Michael Maslowski, CEO, bought 3,000 with an average share price of $2.06 per share and the total transaction amounting to $6,180.00.
- On 12/11/2017 Randal J Kirk, Major Shareholder, bought 2,727,273 with an average share price of $0.77 per share and the total transaction amounting to $2,100,000.21.
- On 12/2/2016 David Pernock, Chairman, bought 50,000 with an average share price of $0.92 per share and the total transaction amounting to $46,000.00.
- On 11/13/2015 David Pernock, CEO, bought 3,000 with an average share price of $5.00 per share and the total transaction amounting to $15,000.00.
- On 8/11/2015 David Pernock, CEO, bought 3,500 with an average share price of $6.54 per share and the total transaction amounting to $22,890.00.
- On 7/27/2015 Randal J Kirk, Major Shareholder, bought 975,987 with an average share price of $5.80 per share and the total transaction amounting to $5,660,724.60.
- On 5/13/2015 David Pernock, CEO, bought 16,600 with an average share price of $4.30 per share and the total transaction amounting to $71,380.00.
About Fibrocell Science Inc (NASDAQ:FCSC)
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Recent Trading Activity for Fibrocell Science Inc (NASDAQ:FCSC)
Shares of Fibrocell Science Inc closed the previous trading session at 1,85 −0,65 26,00 % with 2.04 shares trading hands.